PRISM BioLab Co.,LTD
PRISM BioLab Co.,LTD (206A.T) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for PRISM BioLab Co.,LTD (206A.T), featuring income statements, balance sheets, and cash flow data.
PRISM BioLab Co.,LTD (206A.T) Income Statement & Financial Overview
Analyze PRISM BioLab Co.,LTD’s 206A.T earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|
| Revenue | $125.65M | $90.46M | $99.68M |
| Cost of Revenue | $78.12M | $58.19M | $41.80M |
| Gross Profit | $47.53M | $32.27M | $57.88M |
| Gross Profit Ratio | $0.38 | $0.36 | $0.58 |
| R&D Expenses | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $283.59M | $271.54M | $266.67M |
| Operating Expenses | $283.59M | $271.54M | $266.67M |
| Total Costs & Expenses | -$361.71M | -$329.73M | $308.47M |
| Interest Income | $190000.00 | $344000.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $0.00 | $0.00 | -$24.39M |
| EBITDA | -$190.89M | -$479.56M | -$233.19M |
| EBITDA Ratio | -$1.52 | -$5.30 | -$2.34 |
| Operating Income | -$236.06M | -$239.26M | -$208.80M |
| Operating Income Ratio | -$1.88 | -$2.64 | -$2.09 |
| Other Income/Expenses (Net) | $45.17M | -$240.30M | -$24.39M |
| Income Before Tax | -$190.89M | -$479.56M | -$233.19M |
| Income Before Tax Ratio | -$1.52 | -$5.30 | -$2.34 |
| Income Tax Expense | $605000.00 | $403000.00 | $303000.00 |
| Net Income | -$191.49M | -$479.97M | -$233.49M |
| Net Income Ratio | -$1.52 | -$5.31 | -$2.34 |
| EPS | -$5.30 | -$13.42 | -$7.45 |
| Diluted EPS | -$5.30 | -$13.42 | -$7.45 |
| Weighted Avg Shares Outstanding | $36.10M | $35.77M | $31.35M |
| Weighted Avg Shares Outstanding (Diluted) | $36.10M | $35.77M | $31.35M |
Over the last four quarters, PRISM BioLab Co.,LTD's revenue moved from $99.68M in Q3 2024 to $125.65M in Q1 2025. Operating income in Q1 2025 was -$236.06M, with a strong operating margin of -188%. Despite fluctuations in R&D and SG&A expenses, EBITDA for PRISM BioLab Co.,LTD remained robust at -$190.89M, reflecting operational efficiency. Net income rose to -$191.49M, with an EPS of -$5.30. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan